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Recombinant adenovirus-engineered dendritic cells (Ad.DC) are potent vaccines for induction of anti-viral and anti-
cancer T cell immunity. The effectiveness of Ad.DC vaccines may depend on the newly described ability of Ad.DC to
crosstalk with natural killer (NK) cells via cell-to-cell contact, and to mediate activation, polarization and bridging of
innate and adaptive immunity. For this interaction to occur in vivo, Ad.DC must be able to attract NK cells from
surrounding tissues or peripheral blood. We developed a novel live mouse imaging system-based NK-cell migration test,
and demonstrated for the first time that human Ad.DC induced directional migration of human NK cells across
subcutaneous tissues, indicating that Ad.DC-NK cell contact and interaction could occur in vivo. We examined the
mechanism of Ad.DC-induced migration of NK cells in vitro and in vivo. Ad.DC produced multiple chemokines previously
reported to recruit NK cells, including immunoregulatory CXCL10/IP-10 and proinflammatory CXCL8/IL-8. In vitro
chemotaxis experiments utilizing neutralizing antibodies and recombinant human chemokines showed that CXCL10/IP-
10 and CXCL8/IL-8 were critical for Ad.DC-mediated recruitment of CD56
hiCD16
- and CD56
loCD16
+ NK cells, respectively.
The importance of CXCL8/IL-8 was further demonstrated in vivo. Pretreatment of mice with the neutralizing anti-CXCL8/
IL-8 antibody led to significant inhibition of Ad.DC-induced migration of NK cells in vivo. These data show that Ad.DC can
recruit spatially distant NK cells toward a vaccine site via specific chemokines. Therefore, an Ad.DC vaccine can likely
induce interaction with endogenous NK cells via transmembrane mediators, and consequently mediate Th1 polarization
and amplification of immune functions in vivo.
Introduction
Dendritic cells (DC) and natural killer (NK) cells are central
components of the innate immune system that function at the
interface of innate and adaptive immunity.
1-3 DC are professional
antigen presenting cells (APC) with the unique ability to effici-
ently process and present antigenic epitopes to, and activate
antigen-specific naïve T cells.
2 NK cells are spontaneously cyto-
toxic cells that rapidly recognize and directly eliminate virally-
infected and transformed cells.
4 Both NK cells and DC secrete
proinflammatory and immunoregulatory cytokines, and mediate
inflammation as well as polarization and regulation of both innate
and adaptive immune responses.
1,3,4
An important feature of DC and NK cells is their crosstalk
via cell-to-cell contact leading to reciprocal regulation and
stimulation of type-1 polarization and cytokine secretion.
1,3,5-7
NK cells induce DC maturation and secretion of IL-12p70.
Reciprocally, DC induce NK-cell activation and enhanced IFNc
secretion, tumoricidal activity and proliferation. This early cellular
crosstalk is an essential immunoregulatory mechanism bridging
innate and adaptive immunity, and defining the quality and
magnitude of immune mechanisms that control viral infections
and tumor growth in vivo.
1,3,5,8-10
A number of strategies have been developed to utilize the ability
of DC to stimulate immunity to treat various diseases in clinical
settings. One involves the use of recombinant adenoviral vectors
(AdV) to genetically modify DC to express a protein of interest.
DC engineered with AdV (Ad.DC) are potent immune adjuvants
showing promise as vaccines for viral infection and cancer pre-
vention and therapy.
11,12 Ad.DC acquire an intermediate level of
maturation and have increased ability to stimulate antigen-specific
CD4
+ and CD8
+ T-cell responses.
1,2,5,6,13-15 We have recently
shown that Ad.DC effectively activate resting NK cells and upregu-
late Type-1 cytokine secretion, proliferation, and antitumor activities
via cell-to-cell contact and cooperative activities of transmembrane
TNF (tmTNF) and trans-presented IL-15 (trans-IL-15).
16
NK-cell subsets exhibit specific tissue distributions. Immuno-
regulatory CD56
hiCD16
- NK cells express L-selectin (CD62L, a
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pivotal cell adhesion molecule for engaging lymph node high
endothelial venules) and CCR7, CCR5 and CXCR3 chemokine
receptors.
17,18 These molecules enable CD56
hiCD16
- NK cells to
preferentially localize in lymph node T-cell areas.
19-23 In contrast,
cytotoxic CD56
loCD16
+ NK cells are poorly represented in
lymph nodes, but they comprise the large majority of NK cells
in the peripheral blood, spleen, liver, inflammatory sites and
cancer tissues. They express high levels of CXCR1 and CX3CR1
chemokine receptors, which enable their preferential migration
into inflamed tissues.
19,20,24,25 DC are also present in inflamed
tissues and lymph node T-cell areas,
26,27 and a number of DC-
produced chemokines, including CXCL9/MIG and CXCL10/
IP-10, induce NK-cell chemotaxis.
19,28,29 Therefore, DC could
recruit NK cells in vivo, into inflamed tissues and lymph nodes.
Based on these findings, we hypothesized that Ad.DC-based
vaccine effectiveness might depend on Ad.DC ability to recruit
NK cells and enable their cell-to-cell contact interaction leading
to Th-1 cytokine polarization and amplification of both innate
and adaptive immune functions.
30 Human DC modulate the
repertoire of cytokines and chemokines produced based on
external signals received (LPS, AdV, cytokines).
13,28 In the present
study, we show that Ad.DC induce in vivo mobilization and
migration of human NK cells toward a vaccine site (mediated
largely by CXCL8/IL-8), and in vitro chemotaxis of
CD56
loCD16
+ and CD56
hiCD16
- NK cells via CXCL8/IL-8
and CXCL10/IP-10, respectively. This study is the first to
demonstrate in vivo mobilization and migration of human NK
cells by DC, to identify CXCL8/IL-8 as a crucial chemokine by
which DC recruit NK cells and to determine that Ad.DC
effectively recruit both major subsets of resting NK cells.
Results
Ad.DC induce migration and attract NK cells in subcutaneous
tissues. The efficiency of anticancer or antiviral vaccines may
depend on their ability to induce DC-NK cell crosstalk via cell-to-
cell contact and transmembrane mediators at a vaccine site and
in draining lymph nodes.
7,16 The induction of cell crosstalk at a
vaccine site requires that DC and NK cells are localized in close
proximity or recruited from the surrounding tissues or blood
circulation into the vaccination site. Under physiological condi-
tions, the common skin vaccine site contains DC (Langerhans
cells) and CD56
hiCD16
- NK cells which are mostly distributed in
separate tissue compartments, epidermis and dermis, respec-
tively.
31,32 In contrast, hypodermis lacks both DC and NK cells.
Therefore, a subcutaneous vaccine could induce DC-NK cell
crosstalk if it could recruit DC and NK cells to the immunization
site. A subcutaneously-delivered Ad.DC vaccine could induce
Ad.DC-NK cell crosstalk if Ad.DC could mobilize and attract
NK cells from the dermis and/or peripheral blood.
To directly evaluate the ability of human Ad.DC to attract
NK cells into a vaccine injection site, we developed an IVIS test
for NK-cell migration in subcutaneous tissues of mice. For this
test we used NK cells and iDC labeled with different amine
reactive (NHS ester) near-infrared (NIR) fluorochromes, and
DC transduced with luciferase-encoding AdV (Ad.DC.Luc).
Subcutaneously-injected Ad.DC.Luc or iDC and NK cells
consistently showed well defined and strong transcutaneous
signals for at least 72h in both immunocompetent albino BL6
(B6A) and immunodeficient NOD SCID gamma (NS.IL2Rc
2/2)
mice. Ad.DC.Luc maintained their bioluminescence signal in NS.
IL2Rc
2/2 mice for more than 10d, indicating their ability for
prolonged survival and functionality in vivo (data not shown).
To define the optimal site for the test, multiple injection sites
were tested. Of these, the easiest, the most consistent, and the
most precise measurements were obtained in the lower back. This
location was chosen as the optimal site for in vivo migration tests.
NK-cell migration was detected 24h post-injection, and no addi-
tional migration wasobservedatlater time-points (data notshown).
Ad.DC.Luc and iDC were injected subcutaneously into
contralateral regions of the back. NK cells were injected distally
to a DC injection. Transcutaneous localization of Ad.DC.Luc
(bioluminescence), iDC and NK cells (fluorescence) was
performed using a small animal IVIS at 0h and 24h after cell
injections (Fig. S1). A chemotaxis experiment was considered
positive if we observed at least 5% migration by at least one of the
three measurements taken: distances between the DC signal focus
and the proximal edge, focal point, and distal edge of an NK-cell
signal. In 6/14 (43%) tested mice, NK cells migrated toward Ad.
DC.Luc over a period of 24h after the cell injections (Fig.1;
Fig. S2). In the positive Ad.DC.Luc experiments, we observed
median and mean NK cell-to-Ad.DC.Luc distance decreases of
18% and 22.2% (from proximal edge of the NK-cell signal to the
Ad.DC.Luc signal focus; Fig.1B), 6.9% and 14.9% (between
NK cell and Ad.DC.Luc signal focal points; Fig.1C), and 9.9%
and 13.6% (from the distal edge of NK-cell signal to the Ad.DC.
Luc signal focus; Fig.1D), respectively. In 4/6 assessments, NK-
cell migration toward Ad.DC.Luc was evidenced by all three
measurements demonstrating translocation of the entire NK-cell
population. In 2/6 assessments, the NK-cell signal completely
crossed the initial distance from, and made an overlap with the
Ad.DC.Luc signal (Fig.1A; Ad.DC-best; and data not shown).
In sharp contrast, in 5/5 performed assessments, NK cells did not
migrate toward iDC (Fig.1A–D). These findings demonstrate the
ability of Ad.DC, and inability of iDC, to attract and induce
migration of NK cells in vivo, in subcutaneous connective tissues.
Ad.DC induce chemotaxis of NK cells. To determine the
mechanism of Ad.DC-mediated NK-cell chemo-attraction, we
examined whether Ad.DC produce soluble factors that can induce
chemotaxis of freshly isolated, resting NK cells across a transwell
membrane. We found that Ad.DC and mDC supernatants
induced median chemotaxis of 13.5% and 16.5% of resting NK
cells, respectively, while iDC supernatants had no chemoattractive
activity (Fig.2). The degree of DC supernatant-induced
chemotaxis was donor-dependent, however the overall migration
patterns were the same in all tests. These findings indicate that
Ad.DC and mDC, but not iDC, produce soluble factors capable
of recruiting NK cells.
Ad.DC recruit both CD56
loCD16
+ and CD56
hiCD16
-
NK-cell subsets. Two major subsets of human NK cells, cyto-
toxic CD56
loCD16
+ and immunoregulatory CD56
hiCD16
-, are
differently represented in lymphoid and other normal or inflamed
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tissues, and are believed to be mobilized by different
chemokines. We assessed whether Ad.DC and
mDC-conditioned media could mobilize both NK-
cell subsets. Flow cytometric analysis showed that
both CD56
loCD16
+ and CD56
hiCD16
- NK-cell
subsets migrated toward Ad.DC and mDC super-
natants, and that a similar population distribution
was observed before and after NK-cell migration
(Fig.3). Analysis of purified NK cells prior to migra-
tion confirmed that predominantly CD56
hiCD16
-
cells expressed CD27 (present on mature and lymph
node-infiltrating NK cells) (Fig. S3A).
33,34 We also
confirmed that both NK-cell subsets expressed
NKG2D,
35 NKp30 and NKp46
36,37 (Fig.S3B, C
and D), but not NKp44
38 (data not shown). While
NKG2D expression was consistently found at
similar levels on CD56
loCD16
+ and CD56
hiCD16
-
NK cells (Fig. S3B), NKp30 was expressed at higher
levels on CD56
loCD16
+ and NKp46 was expressed
at higher levels on CD56
hiCD16
- NK cells (Fig.S3C
and D). The patterns of expression of all examined
NK receptors remained similar on NK-cell subsets
that migrated toward Ad.DC supernatant (Fig.S3A,
B, C and D). These data demonstrate that Ad.DC
are capable of recruiting both major subsets of
NK cells.
Ad.DC produce NK-cell-recruiting chemokines.
Our findings that Ad.DC-conditioned media induce
migration of both major subsets of NK cells indicate
that Ad.DC may produce chemokines capable of
mobilizing the NK cells. Cell-free supernatants from
iDC, Ad.DC and mDC were collected 24 h after
treatment and analyzed by Luminex and ELISA for
nine chemokines that have been described to play a
role in NK-cell recruitment: CCL2/MCP-1, CCL3/
MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL19/
MIP-3β, CCL21/6Ckine, CXCL8/IL-8, CXCL9/
MIG and CXCL10/IP-10.
19,28,29 Of the chemokines
Figure2. Ad.DC induce chemotaxis of NK cells in vitro. NK-cell migration induced
by control media (Media) or iDC, Ad.DC or mDC supernatants was measured by FACS.
Box-plot analysis represents distribution of percentages of NK cells that migrated
from the insert into the chamber in four independent experiments. Median values
are shown. * = p , 0.05.
Figure1. Ad.DC induce migration and attract NK cells
in subcutaneous tissues. The in vivo NK-cell chemotaxis
test was performed in seven experiments and 14 mice.
Bioluminescence and fluorescence images were collected
and analyzed as described in Methods and illustrated
in Figure S1. (A) Enlarged image overlays of the best
and average examples of NK-cell (red images) migration
toward Ad.DC.Luc (Ad.DC; blue images), and an average
example of NK-cell (red distal images) migration toward
iDC (red proximal images) over a span of 24h are shown.
Whole mouse image overlays can be seen in Figure S2.
Migration was quantified by measuring the percent of NK
cell-to-DC distance changes between Ad.DC or iDC signal
focus to the (B) proximal edge, (C) focal point and
(D) distal edge of an NK-cell signal. The data were
standardized by calculating the percent change in the
determined distances over a span of 24h after cell
injections. Box-plots represent analysis of all iDC tests
and only positive (6/14) Ad.DC tests.
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tested, only CCL21/6Ckine was not produced by tested DC
types. Compared with iDC, Ad.DC produced increased levels
of all chemokines except for CXCL9/MIG, which was only
produced by IFN-c/LPS-mDC (Fig.4). mDC produced the
highest level of all chemokines. We additionally showed that not
only transfected with AdV encoding for β-galactosidase DC but
also Ad.DC.Luc produced CXCL8/IL-8 at high levels, suggesting
that the effects we report are AdV-mediated and not transgene-
mediated (Fig. S4). These data indicate that AdV transduction
induces a unique chemokine profile in DC that mostly
quantitatively differs from that of mDC, which allows Ad.DC
to effectively recruit both major subsets of NK cells.
NK-cell subsets differentially express chemokine receptors
associated with NK-cell chemotaxis. Because resting NK cells
were actively recruited toward chemokine-rich Ad.DC and mDC
supernatants, we examined whether resting NK cells express
corresponding chemokine receptors to the secreted ligands. We
found that CCR7, CXCR1 and CXCR3 were consistently
expressed on CD56
loCD16
+ NK cells, CCR7 and CXCR3 were
expressed on CD56
hiCD16
- NK cells, while CCR2, CCR3,
CCR4, and CCR5 were solely expressed on the CD56
loCD16
-
NK cells (Table 1; Fig. S5). CD56
loCD16
- NK cells were the
minor NK-cell population, representing , 5% of the total
NK-cell population in more than 90% of tested donors. (Fig.3).
Therefore, we focused our study on CD56
loCD16
+ and
CD56
hiCD16
- NK cells.
Expression levels of CCR7, CXCR1, and CXCR3 on
CD56
loCD16
+ and CD56
hiCD16
- NK cells were differentially
modulated by different DC. CCR7, CXCR1, and CXCR3
expression levels were increasingly downregulated on both NK-
cell subsets following co-incubation with iDC, Ad.DC, and
mDC, respectively (Fig.5A, B and C). Such increasing receptor
downregulation suggested that the receptors were engaging
increasing levels of respective ligands produced by iDC, Ad.DC
and mDC, which in turn induced increasing receptor-ligand
complex internalization.
39-41 These results suggested that CCR7,
CXCR1, and CXCR3 were actively involved in NK cell recruit-
ment by Ad.DC and mDC.
Ad.DC rapidly secrete biologically significant quantities of
CXCL8/IL-8 and CXCL10/IP-10. We found in Ad.DC-con-
ditioned media CCL19/MIP-3β, CXCL8/IL-8 and CXCL10/
IP-10 chemokines, whose respective receptors CCR7, CXCR1
and CXCR3 were consistently expressed on resting NK cells.
Therefore, Ad.DC might utilize CCL19/MIP-3β, CXCL8/IL-8
and CXCL10/IP-10 to attract resting NK cells. For a chemo-
kine to be able to efficiently attract one cell type, it should be
produced rapidly and in relatively large quantities by the other
cell type. We examined the quantities and kinetics of CCL19/
MIP-3β, CXCL8/IL-8 and CXCL10/IP-10 secreted by Ad.DC.
Ad.DC started to secrete CXCL8/IL-8 after 3h, CXCL10/IP-10
after 6h and CCL19/MIP-3β after 12h following AdV trans-
duction. CXCL8/IL-8 and CCL19/MIP-3β were increasingly
secreted up to 48h, while CXCL10/IP-10 up to 24h (Fig.5D).
These data indicate that Ad.DC produced high, moderate and
low levels of CXCL8/IL-8, CXCL10/IP-10 and, CCL19/MIP-3β,
respectively. To determine the levels of the chemokines produced
by Ad.DC, iDC and mDC, we evaluated cell culture-conditioned
media of these DC obtained from a large cohort of healthy donors
for the quantities of secreted CXCL8/IL-8, CXCL10/IP-10 and
CCL19/MIP-3β (Fig.5E). We found that Ad.DC produced high
(1,400 pg/ml), moderate (240 pg/ml), and low (34 pg/ml)
median levels of CXCL8/IL-8, CXCL10/IP-10 and CCL19/MIP-
3β, respectively. Furthermore, Ad.DC always produced these
chemokines more than iDC, but less than mDC. Overall, these
results show that Ad.DC produce CXCL8/IL-8, CXCL10/IP-10
and CCL19/MIP-3β rapidly and at increasing quantities during
an extended period of time, but only produce CXCL8/IL-8 and
CXCL10/IP-10 in significant quantities.
Ad.DC recruit NK cells via CXCL8/IL-8 and CXCL10/IP-10.
We next tested whether CXCL8/IL-8 and CXCL10/IP-10 in Ad.
DC or mDC culture-conditioned media mediate the observed
NK-cell migration. Anti-CXCL10/IP-10 and anti-CXCL8/IL-8
antibodies inhibited 23% and 71%, Ad.DC culture-conditioned
media-induced NK-cell migration, respectively, compared with
the isotype control antibody (Fig.6). Combined anti-CXCL10/
IP-10 and anti-CXCL8/IL-8 caused complete inhibition of NK-
cell migration (Fig.6A). Similarly, CXCL10/IP-10 and CXCL8/
IL-8 blockades inhibited 16% and 60% of mDC culture-
conditioned media-induced NK cell migration, respectively,
indicating that mDC also induced NK-cell chemotaxis mostly
via CXCL10/IP-10 and CXCL8/IL-8. Combined antibody block
did not inhibit NK-cell migration as completely (85.1%) as for
Figure3. Ad.DC and mDC induce chemotaxis of both CD56
loCD16
+ and
CD56
hiCD16
- NK cells. NK cells were evaluated for their ability to migrate
in response to Ad.DC or mDC supernatant. Cells that migrated into
the lower chamber (Migrated Cells) were harvested and their CD56/CD16
co-expression was examined and compared with that of NK cells prior
to migration (Pre-Migration) by FACS. Percentages of positive cells
relative to the whole NK cell population are presented. The results shown
are representative of two experiments.
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Ad.DC, suggesting that other chemokines (e.g., CXCL9/MIG,
CCL19/MIP-3β) secreted by mDC may also play a role in NK-
cell recruitment (Fig. S6).
Since CXCL8/IL-8 was the dominant Ad.DC-secreted NK-
cell chemo-attractant, which induced migration of the majority
of peripheral blood NK cells in vitro, we evaluated whether it
had the same importance in vivo. We performed CXCL8/IL-8
blocking experiments of Ad.DC.Luc-induced NK cell migration
in vivo. In IgG control-treated mice, we observed NK-cell
migration in 6/7 tests [median distance changes of 11.9%
(proximal edge) and 6.15% (focal point) between NK-cell and
Ad.DC.Luc signals], and only in 1/7 anti-CXCL8/IL-8-treated
mice (Fig.6B). These data show that CXCL8/IL-8 plays a
major role in the recruitment of NK cells by Ad.DC in vitro
and in vivo.
CXCL8/IL-8 and CXCL10/IP-10 preferentially recruit
CD56
loCD16
+ and CD56
hiCD16
- NK cells, respectively. To
evaluate which NK-cell subsets were recruited by which Ad.DC-
secreted chemokines, titrating doses of recombinant human
CXCL10/IP-10 and CXCL8/IL-8 were tested for the ability to
induce migration of freshly isolated, resting CD56
hiCD16
-
and CD56
loCD16
+ NK cells (Fig. S7A). At doses of 500 pg/ml
or greater, CXCL8/IL-8 induced specific migration of
CD56
loCD16
+ NK cells, while 5,000 pg/ml of CXCL10/IP-10
induced specific migration of CD56
hiCD16
- NK cells as shown by
specific percentage increases in the post-migration distribution of
NK cell subsets (Fig. S7A). The ability of CD56
hiCD16
- NK cells
to migrate in response to CXCL10/IP-10, but not CXCL8/IL-8,
Figure4. Ad.DC secrete chemokines that mediate NK-cell chemotaxis. iDC, Ad.DC and mDC were plated at 10
6 cells/ml. Cell-free supernatants were
collected from DC cultures and tested for CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, CCL5/RANTES, CCL19/MIP-3b, CCL21/6Ckine, CXCL8/IP-10, CXCL9/MIG
and CXCL10/IP-10 by Luminex and ELISA assays. The results shown are representative of seven experiments.
Table1. Chemokine receptors tested on circulating NK cells by FACS
Receptor expression on:
Ligand Receptor CD56
loCD16
+ CD56
hiCD16
- CD56
loCD16
-
CCL2/MCP-1 CCR2 - - +
CCL5/RANTES CCR3 - - ++
CCL4/MIP-1b,
CCL2, CCL5
CCR4 - - +
CCL3/MIP-1a,
CCL4, CCL5
CCR5 - - +
CCL19/MIP-3b,
CCL21/6Ckine
CCR7 ++ + +++
CXCL8/IL-8 CXCR1 ++ - ++
CXCL9/MIG,
CXCL10/IP-10
CXCR3 ++ +++ ++
-, 0–2%; +, 2–25%; ++, 25–50%; +++, . 50%.
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was additionally confirmed by using highly enriched CD16
- NK
cells (Fig. S7B and C). Together, these data suggest that Ad.DC
produce significant amounts of biologically active CXCL8/IL-8
and CXCL10/IP-10 capable of recruiting CD56
loCD16
+ and
CD56
hiCD16
- NK cells, respectively.
Discussion
DC transduced with tumor-associated antigen-encoding AdV
efficiently stimulate antigen-specific adaptive CD8
+ and CD4
+
T-cell responses in vitro and in cancer patients,
12,15,42 and
Figure5. Expression levels of CCR7, CXCR1 and CXCR3 chemokine receptors on NK cells are decreased following co-culture with DC and Ad.DC secrete
significant amounts of CXCL8/IL-8 and CXCL10/IP-10 but not CCL19/MIP-3b. NK cells were cultured alone (NK) or with iDC, Ad.DC or mDC (NK + iDC,
NK + Ad.DC, and NK + mDC, respectively) for 24h. Afterwards, (A) CXCR1, (B) CXCR3 and (C) CCR7 expression levels were measured on harvested
CD56
loCD16
+ and CD56
hiCD16
- NK cells using FACS. The results shown are MFI and representative of three experiments. (D) Time courses of CXCL8/IL-8,
CXCL10/IP-10 and CCL19/MIP-3b secretion by Ad.DC were measured. (E) CXCL8/IL-8, CXCL10/IP-10 and CCL19/MIP-3b secreted in iDC, Ad.DC and
mDC-conditioned media were measured. For all tests, 10
6 DC/ml were plated and cultured. Cell culture-conditioned media were collected at different
time points between 3h and 48h (D), or at 24h (E) of DC cultures, and tested for CXCL8/IL-8, CXCL10/IP-10 and CCL19/MIP-3b by Luminex and ELISA
assays. (D) Results shown are pg/ml and representative of three experiments. (E) Data are box-plots, medians and ranges of 7 to 36 experiments.
n = number of donors tested. * = p , 0.05.
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represent a promising cancer vaccine.
11,12 Ad.DC also effectively
stimulate innate immunity by activating NK cells and amplifying
their type-1 immune functions and antitumor activities via
tmTNF and trans-IL-15.
16 This contact-mediated Ad.DC-NK
cell crosstalk may be also critical for activation and polarization
of adaptive immune responses, and therefore effectiveness of
Ad.DC-based vaccines. Here we examine whether Ad.DC can
recruit NK cells, an essential first step that could lead to Ad.DC-
NK cell contact, interaction and activation in vivo. We demon-
strate for the first time that Ad.DC can induce migration of
spatially distant NK cells, which could lead to Ad.DC-NK cell
engagement in a subcutaneous vaccine site. Furthermore, we
show that Ad.DC secrete a number of chemokines and effectively
induce chemotaxis of major resting NK-cell subsets via different
chemokines in vitro.
DC and NK cells are present in separate tissue compartments
in the skin, and they normally do not form cell-to-cell contacts
and do not crosstalk. However, under inflammatory conditions
such as atopic dermatitis and autoimmune disease of the skin
(psoriasis, lichen planus and pemphigus vulgaris) NK cells
are recruited in large numbers to skin lesions
43 and could
infrequently be seen in direct contact with DCs.
44,45 NK
cells are found to deeply penetrate non-vascularized
epidermis which contains Langerhans cells, demonstrating
their ability to move and migrate through dense, solid tissue
toward an inflamed locus containing DC.
45 Therefore, the
recruitment of NK cells to an inflamed skin lesion can
occur from both the peripheral blood and the dermal pool
of NK cells. Ad.DC vaccine could be regarded as a rich
source of proinflammatory cytokines and chemokines that
can instantly create an inflammatory environment at the
injection site. Our demonstration that Ad.DC can induce
migration of NK cells in hypodermis suggests that an
Ad.DC vaccine is capable of efficiently attracting and,
likely interacting with NK cells from the neighboring
dermis and peripheral blood.
We show that AdV transduction of DC leads to early
and sustained production of several chemokines associated
with NK-cell migration, including CCL2/MCP-1, CCL3/
MIP-1a, CCL4/MIP-1β, CCL5/RANTES, CCL19/MIP-
3β, CXCL8/IL-8, and CXCL10/IP-10.
17-19,29 Among
these chemokines, CXCL8/IL-8 and CXCL10/IP-10
induce significant chemotaxis of peripheral blood NK
cells. As CD56
loCD16
+ NK cells selectively express
CXCR1, the CXCL8/IL-8 receptor, both Ad.DC-
conditioned media and recombinant CXCL8/IL-8 induce
chemotaxis of CD56
loCD16
+ NK cells. On the other hand,
as CD56
hiCD16
- NK cells preferentially express CXCR3,
the CXCL010/IP-10 receptor, both Ad.DC-conditioned
media and recombinant CXCL010/IP-10 recruit
CD56
hiCD16
- NK cells. Of the chemokines analyzed, only
production of CXCL9/MIG is restricted to LPS/IFNc
mDCs. These data support previous observations that
CXCL9/MIG is an IFNc-inducible chemokine.
46
Another chemokine found to be produced by Ad.DC,
which possibly could play a role in the recruitment of
NK cells, is CCL19/MIP-3β. This chemokine is produced by
Ad.DC at likely insufficient quantities to induce chemotaxis in
vitro. However, we find that CCR7 (CCL19/MIP-3β receptor)
expression undergoes downregulation in NK cell-DC co-cultures,
suggesting that the receptor might engage its respective ligand,
and as a consequence, the receptor-ligand complex is inter-
nalized. This could mean that, in close proximity, Ad.DC-
produced CCL19/MIP-3β could trigger CCR7. However,
because of its low levels of secretion, the role of the CCL19/
MIP-3β chemokine in Ad.DC-induced recruitment of NK cells
remains questionable.
DC play a crucial role in initiating the innate immune res-
ponse in the periphery. DC express pattern-recognition receptors,
such as Toll-like receptors (TLR), which recognize conserved
pathogen-associated molecular patterns. TLR ligation and activa-
tion induce a genetic program that is critical for host defense,
including the induction of certain chemokines. It has been
previously shown that CXCL10/IP-10 is preferentially induced
by the TLR4 agonist Escherichia coli LPS, while CXCL8/IL-8
Figure6. Ad.DC can recruit NK cells via CXCL8/IL-8 and CXCL10/IP-10.
(A) Chemotaxis assay using Ad.DC supernatants and NK cells was performed
as described in Figure2. Control wells contained media only (Media). Specific
chemokines found in Ad.DC supernatants were blocked with isotype control IgG
(mIgG), anti-CXCL10/IP-10 (aIP-10), anti-CXCL8/IL-8 (aIL-8) and joint anti-
CXCL10/IP-10 and anti-CXCL8/IL-8 (aIP-10 + IL-8) antibodies. Values represent
means + SEM of percentages of NK cells that migrated of duplicate tests.
Data are representative of seven experiments. (B) Ad.DC-induced migration
of NK cells was assessed in mice following intraperitoneal injections of anti-
CXCL8/IL-8 (aIL-8) or isotype control (IgG) antibodies. Four experiments were
performed using eight mice. Six mice had duplicate tests in both flanks, and
in total seven tests were performed for each antibody group. Migration was
quantified by measuring the distance between Ad.DC signal focal point
to the proximal edge and focal point of an NK-cell signal. Data were collected
and standardized as described in Figure1. Box-plots represent data distribution
of all seven iDC and Ad.DC tests performed. * = p , 0.05.
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is preferentially induced by the TLR2-specific agonists Staphylo-
coccus aureus peptidoglycans and yeast zymosan.
29 Here we report
that both of these chemokines, as well as a number of other
chemokines, are induced by AdV infection, and LPS/IFNc
stimulation. To date, no AdV-associated TLR ligand has been
identified, and the exact mechanism of AdV induction of DC
maturation and subsequent NK-cell crosstalk is unknown.
Previous studies have indicated that AdV induction of DC
maturation and upregulation of antigen presenting machinery is
dependent on AdV structures.
13,47,48 Therefore, viral structures
could be also responsible for AdV induction of chemokine
secretion by DC.
The effectiveness of Ad.DC vaccines might ultimately depend
on their ability to produce chemokines, and inflammatory and
immunoregulatory cytokines for extended periods of time,
allowing Ad.DC to recruit, engage, and activate NK and T cells.
Our in vitro data demonstrate that CXCL8/IL-8 and CXCL10/
IP-10, as well as CCL19/MIP-3β, are secreted at the highest
levels during the initial 24h after AdV transduction. These data
are substantiated by our in vivo experiments, which suggest that
the initial 24h post AdV infection are critical for the recruitment
of NK cells, and likely other lymphocytes. Simultaneous secretion
of the proinflammatory chemokine CXCL8/IL-8 and immuno-
regulatory chemokines CXCL10/IP-10 and CCL19/MIP-3β by
Ad.DC vaccine in situ could recruit and stimulate both cyto-
toxic CD56
loCD16
+ and immunoregulatory CD56
hiCD16
- NK
cells. However, as dermal NK cells are CD56
hiCD16
- and
spatially the closest NK cells to a subcutaneous vaccine,
31 these
NK cells would be the first and likely the most numerous NK
cells to be recruited by a subcutaneous Ad.DC vaccine. These
NK cells could, via TNF and IFNc secretion, further pro-
mote AdV-induced DC maturation and resistance to NK-cell
mediated killing, and their ability to migrate to draining lymph
nodes. CD56
loCD16
+ NK cells could also be recruited from the
peripheral blood to the immunization site, and, after activation
by Ad.DC, they could eliminate remaining immature Ad.DC.
Following their full maturation at the vaccination site, Ad.DC
could migrate to a draining lymph node, where they could recruit
and interact with the resident immunoregulatory CD56
hiCD16
-
NK cells,
49 and induce their activation and Th1 polarization,
and consequently mediate a robust and appropriate adaptive
T-cell response.
50 These possibilities remain to be tested, and
the findings would have direct biological relevance and clinical
application. They could suggest that chemokine production and
NK-cell recruitment could be indications of an Ad.DC vaccine
potency.
12
In conclusion, we show that Ad.DC effectively induce
migration of NK cells in vivo, and chemotaxis of major NK-cell
subsets in vitro. The chemotaxis is mediated by specific
chemokines produced by Ad.DC. These functions of AdV.DC
coupled with their ability to crosstalk with, activate and polarize
NK cells, make them potent activators of innate immunity. The
study also newly defines CXCL8/IL-8 as a crucial chemokine
by which DC recruit CD56
loCD16
+ NK cells. As Ad.DC also
potently stimulate polyclonal anti-tumor T-cell responses, they
represent a highly potent vaccine, which simultaneously induces
activation, polarization and bridging of innate and adaptive
immunity, and consequent mounting of enhanced anti-tumor
immune functions.
Materials and Methods
Reagents. NK-cell phenotype was evaluated using fluorochrome-
conjugated antibodies against CD69-FITC, CD27-FITC, CD56-
PE (BD PharMingen, San Jose, CA), CD3-APC, NKG2D-PE,
NKp30-PE, NKp44-PE, NKp46-PE, CD16-ECD (Beckman
Coulter, Fullerton, CA), CXCR1-PE, CCR1-PE, CCR2-PE,
CCR5-PE (R&D Systems, Minneapolis, MN), CCR3-PE,
CCR4-PE, CCR6-PE, CCR7-PE-Cy7, and CXCR3-PE (BD
PharMingen). DC phenotype was tested as described.
16
Neutralization of chemokines in DC supernatants and in vivo
was performed with blocking antibodies specific for human
CXCL8/IL-8, and CXCL10/IP-10. Mouse IgG1 isotype non-
reactive monoclonal antibody (R&D) was used as a negative
control. Recombinant human CXCL8/IL-8 and CXCL10/IP-10
(R&D) were used for chemotaxis assays.
Recombinant AdV vectors. AdV vectors encoding E. coli
β-galactosidase gene (Ad.LacZ) and firefly luciferase (Ad.Luc)
were obtained from the University of Pittsburgh Vector Core
Facility. Ad.LacZ and Ad.Luc are E1/E3-deleted and replication-
defective. Multiplicity of infection (MOI) is calculated based on
plaque forming units (pfu) per ml.
Mice. Eight week old T, B and NK-cell deficient NS.IL2Rc
2/2
and B6A female mice were obtained from the Jackson Labora-
tory. Mice were housed at the University of Pittsburgh Cancer
Institute’s AAALAC-accredited animal facility. Animal studies
were performed in accordance with a protocol approved by the
University of Pittsburgh Institutional Animal Care and Use
Committee.
Isolation of peripheral blood mononuclear cells (PBMC).
Peripheral blood was obtained from 50 healthy donors with their
written consent, under an IRB-approved protocol (UPCI 04-
001). PBMC were separated from blood using Ficoll-Hypaque
gradient centrifugation (Cellgro; Mediatech, Inc.).
DC preparation for in vitro experiments. DC were generated
from purified human peripheral blood CD14
+ monocytes as
described.
16 For chemotaxis experiments, iDC were resuspended
in RPMI 1640 media (Invitrogen) supplemented with 0.5%
bovine serum albumin (Fisher Scientific) and were either
untreated (iDC), transduced with Ad.LacZ or Ad.Luc vectors
using 500 MOI (Ad.DC) or matured with IFN-c (1,000 IU/ml;
PeproTech, Inc.) and LPS (250 ng/ml; Sigma) (mDC). DC were
incubated at 37°C for an additional 24–48h. Supernatants were
tested for chemokines, and chemotaxis activity.
NK-cell isolation. NK cells were purified from freshly-isolated
PBMC by negative MACS selection using the human NK-cell
isolation kit (Miltenyi Biotech), according to the manufacturer’s
protocol. CD16
- NK cells were obtained by negative selection
of purified NK cells using anti-human CD16 microbeads
(Miltenyi Biotech). For chemotaxis experiments, NK cells were
resuspended in RPMI 1640 media supplemented with 0.5%
bovine serum albumin at a concentration of 2.5  10
6 cells/ml.
www.landesbioscience.com OncoImmunology 455© 2012 Landes Bioscience.
Do not distribute.
In vivo NK-cell migration test. Test was performed in NS.
IL2Rc
2/2 and B6A mice. iDC were either labeled with VivoTag
1
680 XL (PerkinElmer) NHS ester NIR fluorochrome or
transduced with Ad.Luc vector using 4,000 MOI for 3h in
AIM-V media. Autologous NK cells were freshly isolated, and
labeled with VivoTag-S
TM 750 fluorochrome (PerkinElmer). After
labeling, DC and NK cells were resuspended in ice cold PBS
(16.5–33  10
6/ml). B6A or NS.IL2Rc
2/2 mice were anesthe-
tized with Isoflurane (Wester Veterinary; Sterling, MA), shaved,
and their skin was labeled with a Fisherbrand Marking Pen
(Fisher Scientific) for guided injections and data analyses. Thirty
microliters of the DC and NK-cell suspensions were injected
subcutaneously into a shaved mouse back, parallel to the spine, at
a mutual distance of 0.5–1 cm. For chemokine-blocking experi-
ments, anti-CXCL8/IL-8 or isotype control antibodies were
injected intraperitoneally (R&D; 100 mg/mouse) prior to cell
injections. Animals were examined using the small animal in vivo
imaging system (IVIS; IVIS
1 200 Series) immediately after cell
injections (0h), as well as 24h, 48h and 72h later. Prior to IVIS
analysis, mice were intraperitoneally injected with D-luciferin
potassium salt solution (200 ml/mouse of 30 mg/ml stock
solution; Gold Biotechnology; St. Louis, MO). Ten minutes
following the injection, the luciferin/luciferase reaction occurring
in Ad.Luc-transduced DC, and resulting bioluminescence was
measured using the IVIS. Subsequently, iDC and NK cell
fluorescence signals were analyzed using the Cy5.5 and ICG
channels, respectively. Images were obtained and analyzed with
Living Image
1 v4 program (Caliper Life Sciences, Inc.). DC and
NK-cell image overlays were constructed using the Adobe
Photoshop v6.0 (Adobe Systems Inc.). To precisely measure
NK-cell migration, a 20x20 mm grid was constructed, and, with
the guidance of drawn skin landmarks, placed over a DC-NK cell
image overlay using Microsoft Office PowerPoint 2007. A red
quadrant marked the starting NK-cell location at 0h. The same
grid, with the red quadrant, was carried over to the 24h image,
and positioned the same way as for the 0h overlay using the
guiding skin labels (Fig. S1). NK-cell migration was examined by
measuring the distances between the DC signal focus (point of
highest bioluminescence/fluorescence intensity) and the proximal
edge, focus, and distal edge of an NK-cell signal at 0h and 24h
post-injection using digital calipers. The data were standardized
by calculating the percent change in the DC-NK-cell distance.
Migration was considered positive if we observed at 24h more
than 5% decreases of the 0h distances between DC and NK cells
by at least one of the three measurements.
In vitro NK-cell chemotaxis test. Experiments were performed
in 24-well plates with 5 mm-pore size polyester membrane inserts
(Corning Inc.). Wells were filled with 500ml of DC supernatants
or RPMI 1640 media supplemented with 0.5% bovine serum
albumin and recombinant chemokines at indicated concentra-
tions. Control wells were filled with media only. To neutralize
specific chemokines, anti-CXCL8/IL-8, CXCL10/IP-10, CCL2/
MCP-1 or corresponding isotype control antibodies (R&D,
20mg/ml) were added to Ad.DC or mDC supernatants. 2.5  10
5
of allogeneic NK cells were seeded in 100ml of media in the
transwell insert. After 90min of incubation, NK cells that
migrated into the well were harvested. Their numbers and
phenotype were analyzed by FACS. Migration was presented as
a percent of NK cells that migrated from the insert into the well.
All tests were performed in duplicates and data are means ±
standard error.
Cell phenotype analysis. One step staining of cellular antigens
was performed using fluorochrome-conjugated primary antibodies
as previously described.
13,16
DC/NK-cell coculture. Autologous DC and NK cells were
cocultured as previously described.
16
Chemokine measurement. DC culture supernatants were
assessed for CCL2/MCP-1, CCL3/MIP-1a, CCL4/MIP-1β,
CCL5/RANTES, CXCL8/IL-8, CXCL9/MIG and CXCL10/
IP-10 by Luminex arrays (Biosource, Immunologic Monitoring
Lab); and ELISA for CCL19/MIP-3β and CCL21/6Ckine
(R&D).
Statistical analysis. One-sided paired t-test analyses were used
to estimate statistical significance of differences of obtained
chemokine secretion and NK-cell migration data. p values #0.05
were considered to be statistically significant. In vivo NK-cell
migration and the distribution of the chemokine amounts
produced were analyzed using box-plots constructed with NCSS
2000 Statistical Software (Kaysville, UT).
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